The LumiraDx SARS-CoV-2 Antibody Test detects SARS-CoV-2 total antibody in a finger prick blood drop with results in 11 minutes. The LumiraDx SARS-CoV-2 Ab Test is offered on the same Platform as the LumiraDx SARS-CoV-2 antigen test, giving healthcare providers access to testing virus presence as well as previous exposure and development of antibody response on the same easy-to-use Platform.
The LumiraDx SARS-CoV-2 Ab Test is designed to be used in health care settings to quickly identify individuals with an adaptive immune response to COVID-19, indicating recent or prior infection. The rapid microfluidic immunofluorescence assay detects total antibodies to SARS-CoV-2 in human whole blood (capillary fingerstick or venous), plasma or serum. In clinical studies, the LumiraDx SARS-CoV-2 Ab Test demonstrated 100% positive agreement and 100% negative agreement compared to RT-PCR in fingerstick and plasma samples collected from patients more than 8 days post RT-PCR.